Johnson & Johnson (NYSE:JNJ) on Friday after hours released data from the OMNY-AF pilot study, a prospective, single-arm, multi-center trial.
The study pairs the OMNYPULSE Catheter, a 12 mm large-tip focal catheter featuring contact-force sensing and bipolar, biphasic pulse delivery, with the TRUPULSE Generator.
The integrated design combines precise mapping, controlled energy delivery, and live feedback through the PF index on the CARTO 3 System.
The OMNYPULSE Platform is not currently approved in any region of the world.
The study reported a 90% 12-month freedom from AFib with zero procedure-related adverse events, which could be a significant development for the company’s cardiovascular treatment portfolio, even as broader markets experienced mixed performance.
OMNY-AF Study Shows 90% AFib Freedom
The OMNY-AF pilot study evaluated the investigational OMNYPULSE Platform for treating symptomatic paroxysmal atrial fibrillation (AFib) and showed 100% acute procedural success across a 30-patient cohort.
AFib is an irregular, often rapid heart rate that occurs in temporary episodes, starting and stopping on its own, usually lasting from a few minutes to seven days.
Notably, 56.7% of cases were performed with zero fluoroscopy, reinforcing the platform’s safety and efficiency profile.
Additionally, the study highlighted that the VARIPULSE platform maintained a low neurovascular event rate of 0.22% among 6,811 patients, showcasing its favorable safety outcomes.
The data was presented at the Annual AF Symposium.
The broader market experienced a decline on the previous trading day, with the Nasdaq down 0.47% and the S&P 500 losing 0.22%. Johnson & Johnson’s stock move comes as the Healthcare sector gained 0.26%, suggesting that the stock is underperforming despite positive sector conditions.
Analyst Consensus & Recent Actions:
Johnson & Johnson stock carries a Buy Rating with an average price forecast of $217.81. Recent analyst moves include:
- RBC Capital: Outperform (Raises Target to $255.00) (Feb. 3)
- Morgan Stanley: Upgraded to Overweight (Raises Target to $262.00) (Jan. 28)
Valuation Insight: While the stock trades at a fair P/E multiple, the strong consensus and rising estimates suggest analysts view the growth prospects as justification for the current valuation.
JNJ Scores High on Benzinga Edge Momentum
Below is the Benzinga Edge scorecard for Johnson & Johnson, highlighting its strengths and weaknesses compared to the broader market:
- Value: 20.25 — Trading at a steep premium relative to peers.
- Quality: 13.76 — Balance sheet remains healthy.
- Momentum: 88.55 — Stock is outperforming the broader market.
The Verdict: Johnson & Johnson’s Benzinga Edge signal reveals a classic ‘High-Flyer’ setup. While the Momentum (88.55) confirms the strong trend, the low Value (20.25) score warns that the stock is priced for perfection—investors should ride the trend but use tight stop-losses.
JNJ Price Action: Johnson & Johnson shares were down 0.01% at $239.96 during premarket trading on Monday, according to Benzinga Pro data.
Photo via Shutterstock
Recent Comments